Drugs / CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06447987 | Nov 2024 → Dec 2026 | precursor B-cell acute lymphoblastic leukemia | City of Hope Medical Center | Suspended | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06447987 ↗ |
| Modality | Cell therapy | “CAR T-cell therapy is a treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells.” NCT06447987 ↗ |
| Route | Intravenous | “Given IV” NCT06447987 ↗ |